- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02634151
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins (ROYAL-1)
June 3, 2020 updated by: NeuroBo Pharmaceuticals Inc.
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of gemcabene 600 mg QD compared to placebo in patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy.
Patients with HeFH, ASCVD, or otherwise uncontrolled, may be included with baseline LDL-C value ≥ 100 mg/dL.
Subjects were randomized 1:1 to gemcabene 600 mg once daily (QD) or placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
105
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Central Research Associates, Inc.
-
-
California
-
Beverly Hills, California, United States, 90211
- Westside Medical Associates of Los Angeles
-
Huntington Park, California, United States, 90255
- National Research Institute
-
Los Angeles, California, United States, 90057
- National Research Institute
-
-
Florida
-
Atlantis, Florida, United States, 33462
- Atlantic Clinical Research Collaborative- Cardiology
-
Boca Raton, Florida, United States, 33434
- Excel Medical Clinical Trials
-
Jacksonville, Florida, United States, 32216
- Jacksonville Center for Clinical Research
-
Jupiter, Florida, United States, 33458
- Health Awareness, Inc.
-
Maitland, Florida, United States, 32751
- Meridien Research, Inc.
-
Port Orange, Florida, United States, 32127
- Progressive Medical Research
-
Tampa, Florida, United States, 33626
- Varkey Medical
-
-
Illinois
-
Evanston, Illinois, United States, 60201
- Evanston Premier Healthcare Research, LLC
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Midwest Institute for Clinical Research
-
-
Kentucky
-
Louisville, Kentucky, United States, 40213
- L-MARC
-
-
New York
-
New Windsor, New York, United States, 12553
- Mid-Hudson Medical Research
-
Rochester, New York, United States, 14609
- Rochester Clinical Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
- Sentral Clinical Research Services
-
Cincinnati, Ohio, United States, 45246
- Sterling Research Group, Ltd.
-
Cincinnati, Ohio, United States, 45219
- Sterling Research Group, Ltd.
-
-
Pennsylvania
-
Lansdale, Pennsylvania, United States, 19446
- Green and Seidner Family Practice Associates
-
-
Texas
-
Houston, Texas, United States, 77027
- Associates in Medicine
-
San Antonio, Texas, United States, 78229
- Diagnostics Research Grup
-
Sugar Land, Texas, United States, 77479
- Sugar Lakes Family Practice
-
-
Virginia
-
Richmond, Virginia, United States
- National Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
- Provision of written and signed informed consent (by subject or legal guardian) prior to any study-specific procedures;
- Male or female (neither pregnant or lactating) ≥ 18 years of age at the time of consent;
- Currently on a stable, low-fat, low-cholesterol diet in combination with allowed statin doses as described in Table 1, with or without ezetimibe 10 mg QD for at least 12 weeks prior to the Screening Visit;
- Fasting LDL-C value ≥ 100 mg/dL (2.59 mmol/L) at the Screening Visit;
- Physical examination, including vital signs, that is within normal limits or clinically acceptable to the Investigator;
- Weight ≥ 50 kg; with a body mass index (BMI) ≤ 45 kg/m2
- Subjects with Type 2 diabetes who take anti-hyperglycemic agents must be on a stable regimen for at least 3 months, with no planned changes in medications for the study duration.
Exclusion Criteria
- Abnormal liver function test at the Pre-Screening or Screening Visit (AST or ALT) > 2x ULN (upper limit of normal), total bilirubin > 1.5x ULN, or alkaline phosphate > 2x ULN based on appropriate age and gender normal values. Subjects with bilirubin > 1.5x ULN and a history of Gilbert's syndrome may be included; reflexive direct bilirubin testing will be used to confirm Gilbert's syndrome;
- Moderate (Grade B) or severe (Grade C) chronic hepatic impairment according to the Child-Pugh classification;
- Active liver disease (e.g. cirrhosis, alcoholic liver disease, hepatitis B, hepatitis C, autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, known diagnosis of HIV or AIDS;
- Triglyceride value ≥ 500 mg/dL at the Pre-Screening Visit or the Screening Visit;
- Moderate to severe renal insufficiency define as an estimated GFR < 60mL/min/1.73m (calculated using the Chronic Kidney Disease Epidemiology Collaboration equation) at the Pre-Screening Visit or Screening Visit;
- Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating female with greater than trace hematuria) confirmed by reflexive urine protein:creatinine ration testing;
- Uncontrolled thyroid disease; hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal or > 1.5x ULN, respectively, based on results from the Pre-Screening Visit or the Screening Visit. If controlled, treatment should be stable for at least 3 months prior to Screening;
- Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (hemoglobin A1c value > 8.5% based on results from the Pre-Screening or Screening Visit, or taking a thiazolidinedione (i.e. pioglitazone or rosiglitazone);
- New York Heart Association Class III or IV heart failure;
- Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or other major cardiovascular events resulting in hospitalization within 3 months of the Screening Visit. Subjects with adequately treated stable angina, per Investigator assessment, may be included;
- Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Day 1 prior to dosing ECG (QTcF > 450 msec for men and > 470 msec for women) or known family history of prolonged QT or unexplained sudden cardiac death;
- Uncontrolled hypertension, defined as sitting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg, and confirmed by repeat measurement;
- Currently receiving cancer treatments or, in the Investigator's opinion, at risk of relapse for recent cancer;
- Inadequate wash-out of a PCSK9 inhibitor (8 weeks prior to the Screening Visit), a fibrate lipid-regulating agent (6 weeks prior to the Screening Visit), niacins (4 weeks prior to the Screening Visit), or other lipid-regulating therapies such as bile acid sequestrants (4 weeks prior to the Screening Visit);
- Hypersensitivity to or a history of significant adverse reactions to any fibrate lipid-regulating agent;
- Use of any excluded medications or supplements (e.g. potent cytochrome P450 [CYP] 3A4 inhibitors as described in Appendix D;
- History of drug or alcohol abuse within the past year or inability to comply with protocol requirements, including subjects restrictions (see Section 5.6.3);
- Previously treated with gemcabene (CI-1027), participation in another clinical study of an investigational agent or device concurrently or within 1 month prior the Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if known), whichever is longer, prior to the Screening Visit;
- Any other finding which, in the opinion of the Investigator, would compromise the subject's safety or participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
|
Three placebo tablets administered orally once daily for 12 weeks.
|
Experimental: Gemcabene 600 mg
Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
|
Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent Change From Baseline in LDL-C at Week 12
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in LDL-C by Statin Intensity Stratum
Time Frame: Baseline, Week 12
|
The intensity of statin therapy was determined based on the statin dose.Participants were categorized as high intensity & moderate intensity based on their statin doses.
|
Baseline, Week 12
|
Change From Baseline in LDL-C
Time Frame: Baseline, Weeks 2, 4, 8, 12 and average of weeks 8 and 12
|
Baseline, Weeks 2, 4, 8, 12 and average of weeks 8 and 12
|
|
Percent Change From Baseline in LDL-C
Time Frame: Baseline, average of weeks 8 and 12
|
Baseline, average of weeks 8 and 12
|
|
Percent Change From Baseline in Non-HDL-C
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Change From Baseline in Non-HDL-C
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Percent Change From Baseline in TC
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Change From Baseline in TC
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Percent Change From Baseline in TG
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Change From Baseline in TG
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Percent Change From Baseline in VLDL-C
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Change From Baseline in VLDL-C
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Percent Change From Baseline in HDL-C
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Change From Baseline in HDL-C
Time Frame: Baseline, Weeks 2, 4, 8 and 12
|
Baseline, Weeks 2, 4, 8 and 12
|
|
Number of Participants Achieving LDL-C Reduction of ≥10%
Time Frame: Weeks 4, 8 and 12
|
Weeks 4, 8 and 12
|
|
Number of Participants Achieving LDL-C Reduction of ≥15%
Time Frame: Weeks 4, 8 and 12
|
Weeks 4, 8 and 12
|
|
Number of Participants Achieving LDL-C Reduction of ≥20%
Time Frame: Weeks 4, 8 and 12
|
Weeks 4, 8 and 12
|
|
Number of Participants Achieving an LDL-C Value <100 mg/dL (2.59 mmol/L)
Time Frame: Weeks 4, 8 and 12
|
Weeks 4, 8 and 12
|
|
Percent Change From Baseline in Apolipoprotein B
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Change From Baseline in Apolipoprotein B
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Percent Change From Baseline in Apolipoprotein A-I
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Change From Baseline in Apolipoprotein A-I
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Percent Change From Baseline in Apolipoprotein A-II
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Change From Baseline in Apolipoprotein A-II
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Percent Change From Baseline in Apolipoprotein C-II
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Change From Baseline in Apolipoprotein C-II
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Percent Change From Baseline in Apolipoprotein C-III
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Change From Baseline in Apolipoprotein C-III
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Percent Change From Baseline in Apolipoprotein E
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Change From Baseline in Apolipoprotein E
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Percent Change From Baseline in Lipoprotein(a)
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Change From Baseline in Lipoprotein(a)
Time Frame: Baseline, Weeks 4, 8 and 12
|
Baseline, Weeks 4, 8 and 12
|
|
Percent Change From Baseline in High-sensitivity C-reactive Protein
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
|
Change From Baseline in High-sensitivity C-reactive Protein
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
|
Percent Change From Baseline in Fibrinogen
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
|
Change From Baseline in Fibrinogen
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
|
Percent Change From Baseline in Serum Amyloid A
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
|
Change From Baseline in Serum Amyloid A
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
|
Percent Change From Baseline in Adiponectin
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
|
Change From Baseline in Adiponectin
Time Frame: Baseline, Week 12
|
Baseline, Week 12
|
|
Change From Baseline in Framingham Risk Score
Time Frame: Baseline, Week 12
|
Framingham Risk Score was an estimate of a participant's 10-year risk of developing cardiovascular disease which was computed using sex-specific algorithms based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) : which was derived of participant's age, systolic blood pressure , smoking status, TC, HDL-C, treatment for hypertension, and diabetes status.
Reported score is a percentage.
Change from baseline calculated as mean at week 12 minus mean at baseline.
Negative scores indicate less risk of developing cardiovascular disease.
|
Baseline, Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2016
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
August 1, 2017
Study Registration Dates
First Submitted
December 11, 2015
First Submitted That Met QC Criteria
December 15, 2015
First Posted (Estimate)
December 17, 2015
Study Record Updates
Last Update Posted (Actual)
June 25, 2020
Last Update Submitted That Met QC Criteria
June 3, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GEM-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesteremia
-
Ikaria Bioscience Pty LtdSHANGHAI RONA Therapeutics Co.,Ltd.Not yet recruitingTo Reduce the LDL-C Level in Hypercholesteremia Patients
-
Ikaria Bioscience Pty LtdRecruitingTo Reduce the LDL-C Level in Hypercholesteremia Adult Patients | Combination for Subgroup High LDL-c Patients With Other ComorbiditiesAustralia
-
NeuroBo Pharmaceuticals Inc.Completed
-
University of IoanninaUniversity Hospital, IoanninaCompletedDyslipidemias | Endothelial Dysfunction | Children, Only | Renal Dysfunction | Hypercholesteremia in ChildrenGreece
-
The Cooper InstituteCargillCompleted
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesteremiaChina
-
AstraZenecaCompletedHypercholesteremiaUnited States, France, Norway, Netherlands, Belgium, Germany, Finland, Czech Republic
-
AstraZenecaCompletedHypercholesteremiaBelgium
-
AstraZenecaCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States